Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 1:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 163 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: 40 Gy Radiation Therapy Clear all
Completed Early Phase 1 Interventional

UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients

NCT03158883
View directory record Official record
Conditions
Metastatic Non-small Cell Lung Cancer (NSCLC)
Interventions
Avelumab, Stereotactic ablative radiotherapy (SAR)
Drug · Radiation
Lead sponsor
Megan Daly, MD
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2021 · Synced Sep 12, 2026, 1:48 AM EDT
Withdrawn Phase 2 Interventional

Non-Invasive Cervical Cancer Radiotherapy for Stage IB-IVB

NCT03146039
View directory record Official record
Conditions
Cervical Cancer, Cervical Cancer Stage, Cervical Cancer Stage IB2, Cervical Cancer Stage IB1, Cervical Cancer Stage I, Cervical Cancer Stage IB, Cervical Cancer Stage II, Cervical Cancer Stage IIa, Cervical Cancer, Stage IIB, Cervical Cancer, Stage III, Cervical Cancer Stage IIIB, Cervical Cancer Stage IIIA, Cervical Cancer Stage Iv, Cervical Cancer Stage IVA, Cervical Cancer Stage IVB
Interventions
Radiation Therapy
Radiation
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Feb 4, 2020 · Synced Sep 12, 2026, 1:48 AM EDT
Completed Phase 1 Interventional Results available

Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy

NCT03253744
View directory record Official record
Conditions
Prostate Cancer, Prostatic Neoplasm
Interventions
18F-DCFPyL, Tumor Irradiation, Prostate + tumor irradiation
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 12, 2026, 1:48 AM EDT
Terminated Phase 2 Interventional Results available

Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT00119366
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
iodine I 131 monoclonal antibody BC8, fludarabine phosphate, total-body irradiation, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, cyclosporine, mycophenolate mofetil, laboratory biomarker analysis
Radiation · Drug · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
16 Years to 50 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 11, 2022 · Synced Sep 12, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

Combination Chemoembolization and Stereotactic Body Radiation Therapy in Unresectable Hepatocellular Carcinoma

NCT02513199
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
SBRT, TACE
Radiation · Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 12, 2026, 1:48 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Steroids for Early Treatment of Radiation Retinopathy

NCT03238157
View directory record Official record
Conditions
Radiation Retinopathy
Interventions
Fluocinolone Acetonide (FA) implant
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 12, 2026, 1:48 AM EDT
Withdrawn Phase 2 Interventional

Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC

NCT05608369
View directory record Official record
Conditions
HPV-Related Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Larynx, Squamous Cell Carcinoma of the Oropharynx, Squamous Cell Carcinoma of the Hypopharynx
Interventions
Cisplatin, Radiation therapy, Vorinostat
Drug · Radiation
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Sep 12, 2026, 1:48 AM EDT
Recruiting Phase 3 Interventional

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

NCT07566156
View directory record Official record
Conditions
Urothelial Cancer, Urinary Bladder Neoplasms
Interventions
Enfortumab vedotin, Conventional Radiotherapy, Hypofractionated Radiotherapy, Cisplatin, Fluorouracil, Mitomycin C, Gemcitabine, Pembrolizumab
Drug · Radiation
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
390 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
13
States / cities
Santa Barbara, California • Aurora, Colorado • Newark, Delaware + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 12, 2026, 1:48 AM EDT
Recruiting Phase 1 Interventional

Stereotactic Radiosurgery Dose Escalation for Brain Metastases

NCT02390518
View directory record Official record
Conditions
Brain Metastases
Interventions
Stereotactic Radiosurgery
Radiation
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 12, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Radiotherapy to the Prostate and Dominant Intra-Prostatic Lesion (DIL)

NCT03269422
View directory record Official record
Conditions
Prostate Cancer
Interventions
MR-based image-guided, intensity-modulated radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 12, 2026, 1:48 AM EDT
Completed No phase listed Observational

PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients

NCT03342378
View directory record Official record
Conditions
Squamous Cell Carcinoma, Oropharynx Cancer
Interventions
Intensity modulated radiotherapy (IMRT), PET-MRI
Radiation · Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced Sep 12, 2026, 1:48 AM EDT
Completed Phase 3 Interventional Results available

Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma

NCT00186888
View directory record Official record
Conditions
Retinoblastoma, Retinal Neoplasm
Interventions
Enucleation, Vincristine, Carboplatin, Focal Therapies, External Beam Radiation, Vincristine and Topotecan, Vincristine + Carboplatin + Etoposide, vincristine, cyclophosphamide, and doxorubicin, Vincristine, Carboplatin and Etoposide, Periocular carboplatin, G-CSF
Procedure · Drug · Radiation + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2024
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Sep 12, 2026, 1:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Phase II Trial of SBRT + or - IMRT in Treatment of Patients With Clinically Confined Prostate Adenocarcinoma

NCT02339948
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
SBRT
Radiation
Lead sponsor
GenesisCare USA
Other
Eligibility
18 Years and older · Male only
Enrollment
279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2019
U.S. locations
4
States / cities
Fort Myers, Florida • Plantation, Florida • Farmington Hills, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 12, 2026, 1:48 AM EDT
Completed Phase 2 Interventional Results available

De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal SCC: Follow-up Study

NCT02281955
View directory record Official record
Conditions
Carcinoma, Squamous Cell, Head and Neck Neoplasms, Oropharyngeal Neoplasms
Interventions
Intensity Modulated Radiotherapy (IMRT), Cisplatin (or alternative), Assessment for surgical evaluation
Radiation · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
5
States / cities
Gainesville, Florida • Chapel Hill, North Carolina • Hendersonville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 12, 2026, 1:48 AM EDT
Not yet recruiting Not applicable Interventional

Short Interval Postoperative Stereotactic Body Radiation Therapy (SBRT) After Surgical Intervention for Spine Metastases

NCT07346170
View directory record Official record
Conditions
Spine Metastasis, Stereotactic Body Radiation Therapy (SBRT)
Interventions
Stereotactic Body Radiation Therapy (SBRT), Computed Tomography (CT) Simulation, Magnetic Resonance Imaging (MRI), Questionnaires
Radiation · Procedure · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 12, 2026, 1:48 AM EDT
Completed Phase 1 Interventional

Chemotherapy Combined With Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00059761
View directory record Official record
Conditions
Lung Cancer
Interventions
cisplatin, irinotecan hydrochloride, radiation therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
49
States / cities
Birmingham, Alabama • Burbank, California • Hayward, California + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2015 · Synced Sep 12, 2026, 1:48 AM EDT
Terminated Phase 1 Interventional

Safety Study of SBRT and Docetaxel for Locally Recurrent or Second Primary Squamous Cell Carcinoma of the Head and Neck

NCT02110992
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Stereotactic Radiation
Drug · Radiation
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 12, 2026, 1:48 AM EDT
Completed Not applicable Interventional Results available

Stereotactic Body Radiotherapy for Prostate Cancer

NCT01352598
View directory record Official record
Conditions
Prostate Cancer
Interventions
stereotactic body radiotherapy
Radiation
Lead sponsor
Mercy Research
Other
Eligibility
18 Years and older · Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Sep 12, 2026, 1:48 AM EDT
Recruiting Phase 2 Interventional

Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma

NCT03215719
View directory record Official record
Conditions
Oropharyngeal Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Interventions
Standard Radiation Treatment, Dose-Deescalated Treatment, Cisplatinum
Radiation · Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 12, 2026, 1:48 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease

NCT04588545
View directory record Official record
Conditions
HER2-positive Breast Cancer, Leptomeningeal Metastasis, Leptomeningeal Disease
Interventions
Radiation Therapy, Pertuzumab, Trastuzumab
Radiation · Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
Tampa, Florida • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 12, 2026, 1:48 AM EDT
Completed Not applicable Interventional Results available

Mathematical Model-Adapted Radiation In Glioblastoma

NCT03557372
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
Mathematical Model-Adapted Radiation Fractionation Schedule
Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 25, 2023 · Synced Sep 12, 2026, 1:48 AM EDT
Recruiting Phase 2Phase 3 Interventional

Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer

NCT05288777
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III
Interventions
T-DM1, Capecitabine, External Beam Radiation Therapy 0, External Beam Radiation Therapy 1
Drug · Radiation
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2025 · Synced Sep 12, 2026, 1:48 AM EDT
Withdrawn Phase 1 Interventional

Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma

NCT01618253
View directory record Official record
Conditions
Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatoma, Liver Cancer
Interventions
Sorafenib, Conventional fractionation (2 Gy per day) external beam radiation therapy
Drug · Radiation
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 4, 2013 · Synced Sep 12, 2026, 1:48 AM EDT
Terminated Phase 3 Interventional Results available

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

NCT04866017
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Tislelizumab, Durvalumab, Ociperlimab, Chemotherapy, Radiotherapy
Drug · Radiation
Lead sponsor
BeiGene
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bolivar, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 12, 2026, 1:48 AM EDT